Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin), returned positive top-line results.
Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin) returned positive top-line results.
The Chinese commercial-stage biopharmaceutical company said in a press release that BAT1706 proved equivalent to bevacizumab in overall response rate as a first-line treatment for non-squamous non-small cell lung cancer.
“We are pleased to report on our second proposed biosimilar with positive study results,” said Shenfeng Li, PhD, the chief executive officer of Bio-Thera Solutions. “These results demonstrate the potential of our proposed bevacizumab biosimilar to be a safe and effective treatment option for cancer patients. Bio-Thera is committed to increasing patient access to innovative medicines through the development of high-quality biosimilars.”
Avastin is indicated in the US to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer, along with other conditions.
According to the press release, “BAT1706 works by binding the vascular endothelial growth factor (VEGF) protein.” It has not yet received regulatory approval in any country.
The trial consisted of a multicenter, randomized, double-blind study which evaluated the pharmacokinetics and immunogenicity of BAT1706. Results of the study have yet to be released and the company is developing several other proposed biosimilars including ustekinumab, secukinumab and golimumab.
Separately this week, the FDA requested data for Formycon’s Lucentis biosimilar candidate FYB201, as part of a review process for a biologics license application (BLA). The company stated it will take around 4 months to generate the additional data. However, Bioeq, its licensing partner, announced it would withdraw its BLA for the biosimilar candidate, provide requested data, and resubmit the application after, which may delay approval of the BLA.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.